Aflatoxins (AFs) are mycotoxins, predominantly produced by Aspergillus flavus, A.
parasiticus, A. nomius, and A. pseudotamarii. AFs are carcinogenic compounds causing …

Hepatocellular carcinoma (HCC) represents one of the few cancers for which locoregional
treatments are recognised as being able to cure and/or prolong survival and are included in …

Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …

Background Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC
often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG …

Background Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET,
AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) …

Traditional treatments for intermediate or advanced stage hepatocellular carcinoma (HCC)
such as transarterial chemoembolization (TACE) and anti-angiogenesis therapies were …

Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the
randomized phase II study with tivantinib - PMC Back to Top Skip to main content NIH NLM Logo …

Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the
second leading cause of cancer‐related deaths across the globe. Only a small percentage …

Background Inhibition of the renin–angiotensin system (RAS) was associated with longer
survival in patients with different solid malignancies. Objective The objective of this study …